Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.
Authors: David Shui, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Lawrence Fong, Terence W. Friedlander, Franklin W. Huang, Vadim S Koshkin, Ivan de Kouchkovsky, Julian C. Hong, Osama Mohamad, Felix Y Feng, Rahul Raj Aggarwal, Thomas A Hope, Eric Jay Small, Daniel H Kwon
Journal: Journal of Clinical Oncology (2022)

109 Background: Radiopharmaceuticals, including Ga-68-prostate specific membrane antigen (PSMA)-11, F-18-fluciclovine, and choline C-11, are increasingly used to stage and inform therapies for PCa. Stereotactic body radiation therapy (SBRT) to PET-detected oligometastatic PCa has been shown to improve progression free survival (PFS) compared to observation. However, for men who subsequently develop oligorecurrent disease, outcomes following second SBRT are unknown. Methods: A retrospective, single-center, cohort study was conducted. Pts were identified through electronic health records. Inclusion criteria included pts with oligometastatic (1-5 lesions) PCa detected on PSMA, fluciclovine, or choline C-11 PET who underwent 2 consecutive courses of SBRT to tracer-avid oligometastatic disease between 7/2013 and 7/2021. Exclusion criteria included presence of visceral metastases and pure small cell neuroendocrine PCa. Data on stage, tracer type, concurrent systemic therapy, and prostate-specific antigen (PSA) responses for first SBRT (SBRT1) and second SBRT (SBRT2) were collected. Outcomes included PSA decline of ≥50% (PSA50), ≥90% (PSA90), and PSA-PFS. SBRT2 outcomes were compared based on change of concurrent systemic therapy with SBRT2 (e.g., addition of abiraterone or anti-androgen withdrawal) and PSA50 to SBRT1 using Fisher’s exact text and Wilcoxon rank sum test, respectively. Results: A total of 12 pts met eligibility criteria. At SBRT1, 10 (83%) pts had hormone-sensitive PCa (HSPC) and 2 (17%) had castration-resistant PCa (CRPC). For PET tracers, 7 (58%) used PSMA, 4 (33%) fluciclovine, and 1 (8%) choline. After SBRT1, 12 pts (100%) had a PSA decline, 8 (67%) had a PSA50 response, and 6 (50%) a PSA90 response. Median PSA PFS after SBRT1 was 30mo (95%CI 9-65mo). Six (50%) SBRT1 pts had a concurrent change in systemic therapy. At SBRT2, 8 (67%) pts had HSPC and 4 (33%) had CRPC; 7 (58%) used PSMA and 5 (42%) fluciclovine. After SBRT2, 12 (100%) pts had a PSA decline, 8 (67%) had a PSA50 response, and 8 (67%) a PSA90 response. After SBRT2, median PSA PFS was 23mo (95%CI 12-35mo). Among 7 pts who had a concurrent change in systemic therapy with SBRT2, all (100%) had a PSA50 response; among 5 who did not (4 of whom did not receive any systemic therapy), 1 (20%) had a PSA50 response (P=0.01). Among 8 pts who had a PSA50 response to SBRT1, 7 (88%) had one to SBRT2; among 4 who did not have a PSA50 response to SBRT1, 1 (25%) had one to SBRT2 (P=0.01). No complications related to SBRT were documented. Conclusions: Serial SBRT for oligometastatic PCa detected on fluciclovine, PSMA, or choline PET is feasible and can achieve PSA declines independent of systemic therapy. PSA responses were greater when systemic therapy was changed. This preliminary evidence of benefit, based on PSA responses and PSA PFS, provides rationale for larger, prospective studies of serial SBRT for oligometastatic PCa.